The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

出版年份 2014 全文链接

标题

作者

关键词

出版物

Volume 20, Issue 17, Pages 4549-4558

出版商

American Association for Cancer Research (AACR)

发表日期

2014-06-20

DOI

10.1158/1078-0432.ccr-13-3248

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started